Moderna (NASDAQ:MRNA) PT raised to $106.00

Moderna (NASDAQ:MRNA – Free Report) The price target was raised by Canaccord Genuity Group from $91.00 to $106.00 in a research report released Friday morning, Benzinga reports. They currently have a hold rating on the stock.

Other research analysts have also issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9. HSBC reiterated a downgrade and issued an $86.00 price objective on shares of Moderna in a research note on Monday, February 26. Oppenheimer raised his price target on shares of Moderna from $142.00 to $163.00 and gave the company an outperform rating in a research note on Friday. William Blair reiterated a market performance rating on shares of Moderna in a research note on Monday, April 1. Finally, Royal Bank of Canada raised its price target on shares of Moderna from $125.00 to $135.00 and gave the company an outperform rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Hold and a consensus price target of $129.55.

Get our latest research report on Moderna

Modern price performance

MRNA opened at $122.13 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company has a market cap of $46.81 billion, a price-to-earnings ratio of -7.79 and a beta of 1.57. The company’s fifty-day moving average price is $105.61 and its two-hundred-day moving average price is $94.76. Moderna has a 1-year low of $62.55 and a 1-year high of $142.79.

Moderna (NASDAQ:MRNA – Get Free Report) last reported its earnings results on Thursday, May 2. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to analyst expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company’s revenue for the quarter fell 91.0% compared to the same quarter last year. During the same period last year, the company posted earnings per share of $0.19. As a group, analysts expect Moderna to post -7.47 earnings per share for the current fiscal year.

Buying and selling with insider information

In related news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction on Thursday, February 29. The shares sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now directly owns 8,557 shares in the company, valued at $809,235.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Moderna news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the President now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. Insider Shannon Thyme Klinger also sold 670 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now directly owns 8,557 shares of the company’s stock, worth approximately $809,235.49. The explanation of this sale can be found here. Over the last ninety days, insiders have sold 139,954 company shares worth $14,822,576. Corporate insiders own 15.20% of the company’s shares.

Institutional investors are weighing in on Moderna

A number of hedge funds and other institutional investors have recently increased or decreased their stakes in the company. Empowered Funds LLC increased its position in Moderna by 26.8% during the first quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock valued at $456,000 after purchasing an additional 904 shares during the last quarter. Empirical Finance LLC increased its stake in Moderna by 4.7% in the first quarter. Empirical Finance LLC now owns 8,975 shares of the company’s stock worth $956,000 after purchasing an additional 399 shares in the last quarter. Mawer Investment Management Ltd. increased its stake in Moderna by 6.7% in the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after purchasing an additional 120,621 shares in the last quarter. Advisory Alpha LLC bought a new stake in shares of Moderna worth $394,000 in the first quarter. Finally, John G Ullman & Associates Inc. increased its stake in Moderna stock by 212.3% in the first quarter. John G Ullman & Associates Inc. now owns 11,400 shares of the company’s stock worth $1,215,000 after acquiring an additional 7,750 shares in the last quarter. 75.33% of the shares are currently held by institutional investors.

Moderna company profile

(Get a free report)

Moderna, Inc, a biotechnology company, discovers, develops and commercializes messenger RNA therapies and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases in the United States, Europe and internationally. The respiratory vaccines include vaccines against COVID-19, influenza and respiratory syncytial virus, spikevax and hMPV/PIV3; latent vaccines include cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; public health vaccines consist of Zika, Nipah and Mpox vaccines; and vaccines against infectious diseases, such as vaccines against Lyme and norovirus.

read more

Get news and reviews for Moderna Daily – Enter your email address below to receive a daily summary of the latest news and analyst ratings for Moderna and related companies with MarketBeat.com’s FREE daily email newsletter.